AUS
NZ
UK
CA
USA
IND
Pro Medicus Ltd (ASX:PME) is enjoying a notable boost in its share price, which has risen by 8% following the release of its robust FY24 financial results. The company, renowned for its expertise in healthcare informatics, offers a comprehensive suite of medical imaging software and services to hospitals, imaging centers, and healthcare groups around the globe.
FY24 Financial Highlights
For the year ending June 30, 2024, Pro Medicus reported remarkable financial performance:
- Revenue: Increased by 29.3% to reach $161.5 million.
- Underlying EBIT Margin: Improved to 69.5%, up from 67.2% in the previous year.
- Underlying Profit Before Tax: Rose by 35.3% to $116.5 million.
- Net Profit After Tax (NPAT): Jumped by 36.5% to $82.8 million.
- Final Dividend: Increased by 29.4% to $0.22 per share.
- Full-Year Dividend: Up by 33.3% to $0.40 per share.
- Cash and Financial Assets: Grew by 27.9% to $155.4 million, with no debt on the balance sheet.
Regional Performance and Contracts
Pro Medicus saw significant revenue growth in North America, with an increase of 34.4%. Australian revenue also grew by 5.9%, although European revenue decreased by 6.7% due to a one-off sale to a German hospital in the prior period.
The company secured numerous long-term contracts during FY24, including nine contracts with a minimum total value of $245 million. Notably, Pro Medicus won a substantial $140 million, 10-year contract with Baylor, Scott and White, one of the largest not-for-profit healthcare systems in Texas and the U.S.
Strategic Advantages and Future Outlook
Pro Medicus’ CEO, Dr. Sam Hupert, highlighted the benefits of increasing cloud adoption, which has streamlined implementations and provided a competitive edge. The company’s solutions are adaptable across various market segments, from small radiology practices to large healthcare organizations in the U.S.
The company currently captures just over 7% of the total addressable market in the U.S., and management sees considerable growth potential. Pro Medicus continues to advance its AI and other technologies, with a strong pipeline suggesting a promising outlook.
Opportunities in Europe and Asia are expected to be smaller and more opportunistic compared to the U.S. market.
Evaluation
Pro Medicus’ impressive profit metrics, strong revenue growth, solid balance sheet, and increasing dividend reflect its robust performance. The company’s P/E ratio has been on the rise, reflecting investor confidence and the company’s growth prospects.
Pro Medicus is positioned as a leading player in the ASX healthcare sector, with a substantial runway for future growth and continued expansion in its core markets.
